Corten Capital and Ampersand Capital Partners Complete Acquisition of Beacon Intelligence to Accelerate Growth in Life Sciences R&D Intelligence

Corten Capital, alongside Ampersand Capital Partners, has successfully completed the acquisition of Beacon Intelligence for an undisclosed amount. The transaction, announced on June 30, 2026, marks a significant milestone in the life sciences sector, particularly in enhancing research and development (R&D) intelligence capabilities. Corten Capital now holds the majority stake in Beacon, which was previously part of the Hanson Wade Group, while Ampersand joins as a minority co-investor.

Founded in 2015, Beacon Intelligence was established to fill a critical gap in the availability of structured, granular data related to early-stage drug development. The company has since developed a robust platform that serves over 300 clients globally, including 24 of the 30 largest pharmaceutical companies. Beacon's offerings encompass a unique dataset across 16 modules that cover various complex modalities, such as antibody-drug conjugates (ADCs), bispecifics, and RNA therapeutics, as well as disease-specific data in areas like oncology and neuroscience. The acquisition is expected to facilitate Beacon's growth as an independent entity, allowing it to deepen its data coverage and enhance its platform capabilities.

Corten Capital's investment strategy focuses on partnering with innovative management teams to scale B2B software and data businesses. The firm, which raised €680 million in capital commitments for its second fund in March 2024, aims to leverage its expertise to support Beacon in its next growth phase. The leadership team at Beacon, including CEO Rob Poolman and Chair Sati S. Sian, will remain in place to drive the company's strategic initiatives and operational execution. The involvement of Ampersand Capital Partners, a firm with a strong track record in healthcare investments, further strengthens the support network for Beacon as it transitions to independence.

The life sciences sector is experiencing increased demand for sophisticated data analytics and intelligence solutions, driven by the need for more efficient drug development processes. As pharmaceutical companies face mounting pressure to innovate and reduce time-to-market for new therapies, platforms like Beacon Intelligence are becoming essential tools for decision-making in R&D investments. The acquisition by Corten Capital and Ampersand is poised to enhance Beacon's capabilities and market position, enabling it to better serve the evolving needs of its clients.

In summary, the acquisition of Beacon Intelligence by Corten Capital and Ampersand Capital Partners underscores the growing importance of data-driven insights in the life sciences industry. As the sector continues to evolve, the strategic partnership is expected to position Beacon as a leading intelligence platform for drug development, ultimately contributing to improved outcomes in the pharmaceutical and biotechnology landscapes. The transaction reflects broader trends in the market, where private equity investments are increasingly directed toward companies that can provide critical data and analytics solutions in a rapidly changing environment.